medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2012, Número 3

<< Anterior Siguiente >>

Biotecnol Apl 2012; 29 (3)


Efecto del factor de crecimiento epidérmico humano en la línea celular tumoral A431: análisis de la inhibición del crecimiento tumoral y la expresión génica in vivo

Guillén IA, Camacho H, Fernández ME, Palenzuela DO, Pérez L, Ochagavia ME, Ancizar JA, Tuero AD, Gorovaya L, Mendoza O, Díaz T, Fernández JR, Roca J, Cosme K, Guillén-Nieto GE, Herrera L, Berlanga J, Novoa LI

Idioma: Ingles.
Referencias bibliográficas: 50
Paginas: 155-161
Archivo PDF: 236.43 Kb.


RESUMEN

The historical tag of the epidermal growth factor (EGF) as carcinogenesis promoter has not been uniformly reproduced, since, in some experiments, malignant cells are bound to growth inhibition and apoptosis. The present study intends to obtain additional data on the interaction of EGF with cancer cells by analyzing its effect in vitro on the growth of cultured A431 cells, and in vivo on nude mice xenotransplanted with this cell line; identifying, in addition, the gene expression patterns for a selected group of genes related to EGF and cancer pathways in the solid tumor. EGF-treated animals showed significantly smaller tumor volumes than controls, suggesting cellular growth inhibition mediated by this factor. Similar results were obtained regarding the proliferation of cultured A431 when treated with 2.2, 33 and 165 nM of EGF. These results may imply a common mechanism for the EGF-mediated growth inhibition of A431 cells in both biological conditions (in vivo and in vitro). The action of EGF at nanomolar concentrations may trigger a transient recovery of the tumor suppressor ability of tumor cells through the reduction of the biological action of mutated TP53, cell cycle arrest due to a decrease in Cdk4 expression levels and the initiation of caspase through the activation of CASP9.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265(14):7709-12.

  2. Venturi S, Venturi M. Iodine in evolution of salivary glands and in oral health. Nutr Health. 2009;20(2):119-34.

  3. Kresge N, Simoni RD, Hill RL. Precocious Newborn Mice and Epidermal Growth Factor: the Work of Stanley Cohen. J Biol Chem. 2006;281(10):e10.

  4. Berlanga J. Heberprot-P: experimental background and pharmacological bases. Biotecnol Apl. 2010;27(2):88-94.

  5. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell. 1991;64(2):271-80.

  6. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med. 2009;361(10):1018-20.

  7. Berlanga J, Gavilondo J, García del Barco D, Martín J, Guillén G. Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression. J Carcinogenesis Mutagenesis. 2011;2(1):115. Available from: http://www.omicsonline.org/2157-2518/2157-2518-2-115.php?aid=294.

  8. Berlanga J, Álvarez S, de la Fuente J, López P. Considerations on the transforming potential of the epidermal growth factor. Biotecnol Apl. 1998;15(2):65-9.

  9. Berlanga-Acosta J, Gavilondo-Cowley J, López-Saura P, González-López T, Castro-Santana MD, Lopez-Mola E, et al. Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications. Int Wound J. 2009;6(5):331-46.

  10. Stoscheck CM, Carpenter G. Biology of the A-431 cell: a useful organism for hormone research. J Cell Biochem. 1983;23(1-4):191-202.

  11. Masui H, Castro L, Mendelsohn J. Consumption of EGF by A431 cells: evidence for receptor recycling. J Cell Biol. 1993;120(1):85-93.

  12. Jakus J, Yeudall WA. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene. 1996; 12(11):2369-76.

  13. Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 2008;68(21):8843-51.

  14. Acosta JB, Savigne W, Valdez C, Franco N, Alba JS, del Río A, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. Int Wound J. 2006;3(3):232-9.

  15. Fernández-Montequín JI, Infante-Cristia E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutiérrez W, Artaza-Sanz H, et al. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J. 2007;4(4):333-43.

  16. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, et al. Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J. 2009;6(6):432-43.

  17. Talavera A, Friemann R, Gómez-Puerta S, Martínez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851-9.

  18. Cinza AM, Quintana M, Lombardero J, Poutou R, Pérez E, Pérez LC, et al. Establecimiento de un cultivo discontinuo para la producción del factor de crecimiento epidérmico humano en levaduras. Caracterización del producto. Biotecnol Apl. 1991;8(2):166-74.

  19. Berlanga-Acosta J, Playford RJ, Mandir N, Goodlad RA. Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut. 2001;48(6):803-7.

  20. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14(8):1107-15.

  21. Leung TW, Xue WC, Cheung AN, Khoo US, Ngan HY. Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. Gynecol Oncol. 2004;92(3):866-72.

  22. Rodríguez R, Alarcón TE, Sáchez LB. MADIP: Morphometrical Analysis by Digital Processing. In: Sánchez JS, Pla F. Proceedings of the IX Spanish Symposium on Pattern Recognition and Image Analysis: Benicasim (Castellón), Spain, 16-18 May 2001. Vol. I. Castellón de la Plana: Publicaciones de la Universitat Jaume; 2001. p. 291-8.

  23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.

  24. Martín A, Ochagavía ME, Rabasa LC, Miranda J, Fernández-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics. 2010;11:91.

  25. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, et al. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374-8.

  26. Public Databases for Academic and Non-profit Organizations [Internet]. Wolfenbüttel: BIOBASE Biological Databases. c2000-2001 - [cited 2011 Oct 14]. Available from: http://www.gene-regulation.com/pub/databases.html.

  27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-9.

  28. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005; 21(16):3448-9.

  29. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3.

  30. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002;30(1):42-6.

  31. BioCarta [Internet]. San Diego: BioCarta LLC; c2012 - [cited 2011 Oct 14]. Available from: http://www.biocarta.com.

  32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132:365-86.

  33. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9):e36.

  34. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den Hoff MJ, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009;37(6):e45.

  35. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.

  36. Bernardo JM, Smith AFM. Bayesian Theory. Chichester: Wiley; 1994.

  37. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest. 2007;117(8):2051-8.

  38. Gill GN, Lazar CS. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature. 1981;293(5830):305-7.

  39. Gill GN, Buss JE, Lazar CS, Lifshitz A, Cooper JA. Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells. J Cell Biochem. 1982;19(3):249-57.

  40. Barnes DW. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol. 1982;93(1):1-4.

  41. Santon JB, Cronin MT, MacLeod CL, Mendelsohn J, Masui H, Gill GN. Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res. 1986;46(9):4701-5.

  42. Murayama Y. Growth-inhibitory effects of epidermal growth factor on human breast cancer and carcinoma of the esophagus transplanted into nude mice. Ann Surg. 1990;211(3):263-8.

  43. Amagase H, Tamura K, Okuhira M, Kakimoto M, Amano H, Hashimoto K, et al. Epidermal growth factor prolongs survival time of tumor-bearing mice. Jpn J Cancer Res. 1990;81(5):495-500.

  44. Jones LB, Bean R, McLachlan GJ, Zhu JX. Mixture models for detecting differentially expressed genes in microarrays. Int J Neural Syst. 2006;16(5):353-62.

  45. Williams AC, Miller JC, Collard TJ, Bracey TS, Cosulich S, Paraskeva C. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene. 1995;11(1):141-9.

  46. van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. 2000; 6(6):2138-45.

  47. Prasad KA, Church JG. EGF effects on p53 in MDA-468 human breast cancer cells: implications for G1 arrest. Cell Prolif. 1997;30(2):81-94.

  48. Shinoura N, Sakurai S, Asai A, Kirino T, Hamada H. Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U-87MG glioma cells. Neurosurgery. 2001;49(1):177-86.

  49. Xia L, Yuan YZ, Xu CD, Zhang YP, Qiao MM, Xu JX. Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor of nude mice. World J Gastroenterol. 2002;8(3):455-8.

  50. Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells. Cancer Lett. 2009;283(2):135-42.




2020     |     www.medigraphic.com